Announced
Financials
Sources
Tags
Domestic
Single Bidder
Pending
Acquisition
Private
Merger
Friendly
United States
Majority
genomics
Biotechnology
Private Equity
Synopsis
Invitae, a genetics company, agreed to acquire ArcherDX, a genomics analysis company democratizing precision oncology, for $1.4bn. "From the beginning, Invitae's goal has been to aggregate the world's genetic tests into a single platform in service of our mission to bring comprehensive genetic information into mainstream medicine. Today, we take another major step forward in that effort," Sean George, Invitae CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.